US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

US IPOs and Secondary Offerings

Mobia Medical (MOBI): Medical Device for Stroke Recovery Sets Terms for IPO

Mobia Medical (MOBI): High-Growth Medtech Targeting a New Standard in Stroke Rehab

Mobia Medical (MOBI): Oversubscribed but Unsupported, IPO Falters in Aftermarket Trading

IPOs and Secondary Offerings

Equity Capital Markets

<ul>
<li>Mobia Medical is a commercial-stage medtech company with FDA-approved Vivistim system, the first therapy targeting chronic ischemic stroke motor recovery via vagus nerve stimulation.</li>
<li>The company filed for IPO on April 17, backed by major underwriters, and has rapidly scaled revenue from $15.6M (2024) to $32.0M (2025), a 104.8% increase.</li>
<li>Despite strong growth and over 1,000 implants, Mobia remains loss-making, but targets a large ~$30B U.S. stroke recovery market with limited direct competition.</li>
</ul>


Mobia Medical is a commercial-stage medtech company with FDA-approved Vivistim system, the first therapy targeting chronic ischemic stroke motor recovery via vagus nerve stimulation.
The company filed for IPO on April 17, backed by major underwriters, and has rapidly scaled revenue from $15.6M (2024) to $32.0M (2025), a 104.8% increase.
Despite strong growth and over 1,000 implants, Mobia remains loss-making, but targets a large ~$30B U.S. stroke recovery market with limited direct competition.


モビア・メディカル（MOBI）：脳卒中患者向け医療機器会社のIPO目論見書を覗いてみよう